Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis

References

• Esiashvili N, Anderson C, Katzenstein HM. Neuroblastoma. Curr Probl Cancer 2009; 33:333 - 60; http://dx.doi.org/10.1016/j.currproblcancer.2009.12.001; PMID: 20172369
   PubMed Web of Science ®Google Scholar
• Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007; 369:2106 - 20; http://dx.doi.org/10.1016/S0140-6736(07)60983-0; PMID: 17586306
   PubMed Web of Science ®Google Scholar
• Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3:203 - 16; http://dx.doi.org/10.1038/nrc1014; PMID: 12612655
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5:835 - 44; http://dx.doi.org/10.1038/nrd2130; PMID: 17016424
   PubMed Web of Science ®Google Scholar
• Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66:11851 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-06-1377; PMID: 17178882
   PubMed Web of Science ®Google Scholar
• Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007; 59:561 - 74; http://dx.doi.org/10.1007/s00280-006-0393-4; PMID: 17160391
   PubMed Web of Science ®Google Scholar
• Rahmani M, Nguyen TK, Dent P, Grant S. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Mol Pharmacol 2007; 72:788 - 95; http://dx.doi.org/10.1124/mol.106.033308; PMID: 17595328
   PubMed Web of Science ®Google Scholar
• Yang F, Van Meter TE, Buettner R, Hedvat M, Liang W, Kowolik CM, et al. Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Mol Cancer Ther 2008; 7:3519 - 26; http://dx.doi.org/10.1158/1535-7163.MCT-08-0138; PMID: 19001435
   PubMed Web of Science ®Google Scholar
• Yang F, Brown C, Buettner R, Hedvat M, Starr R, Scuto A, et al. Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. Mol Cancer Ther 2010; 9:953 - 62; http://dx.doi.org/10.1158/1535-7163.MCT-09-0947; PMID: 20371721
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24:4293 - 300; http://dx.doi.org/10.1200/JCO.2005.01.3441; PMID: 16908937
   PubMed Web of Science ®Google Scholar
• Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007; 12:426 - 37; http://dx.doi.org/10.1634/theoncologist.12-4-426; PMID: 17470685
   PubMed Web of Science ®Google Scholar
• Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, et al. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist 2007; 12:191 - 200; http://dx.doi.org/10.1634/theoncologist.12-2-191; PMID: 17296815
   PubMed Web of Science ®Google Scholar
• Yu H, Jove R. The STATs of cancer--new molecular targets come of age. Nat Rev Cancer 2004; 4:97 - 105; http://dx.doi.org/10.1038/nrc1275; PMID: 14964307
   PubMed Web of Science ®Google Scholar
• Haura EB, Turkson J, Jove R. Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2005; 2:315 - 24; http://dx.doi.org/10.1038/ncponc0195; PMID: 16264989
   PubMedGoogle Scholar
• Pathak AK, Bhutani M, Nair AS, Ahn KS, Chakraborty A, Kadara H, et al. Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells. Mol Cancer Res 2007; 5:943 - 55; http://dx.doi.org/10.1158/1541-7786.MCR-06-0348; PMID: 17855663
   PubMed Web of Science ®Google Scholar
• Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10:105 - 15; http://dx.doi.org/10.1016/S1074-7613(00)80011-4; PMID: 10023775
   PubMed Web of Science ®Google Scholar
• Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009; 15:91 - 102; http://dx.doi.org/10.1016/j.ccr.2009.01.002; PMID: 19185844
   PubMed Web of Science ®Google Scholar
• Tawara K, Oxford JT, Jorcyk CL. Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag Res 2011; 3:177 - 89; PMID: 21625400
   PubMedGoogle Scholar
• Ara T, Song L, Shimada H, Keshelava N, Russell HV, Metelitsa LS, et al. Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res 2009; 69:329 - 37; http://dx.doi.org/10.1158/0008-5472.CAN-08-0613; PMID: 19118018
   PubMed Web of Science ®Google Scholar
• Lee H, Deng J, Kujawski M, Yang C, Liu Y, Herrmann A, et al. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med 2010; 16:1421 - 8; http://dx.doi.org/10.1038/nm.2250; PMID: 21102457
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099 - 109; http://dx.doi.org/10.1158/0008-5472.CAN-04-1443; PMID: 15466206
   PubMed Web of Science ®Google Scholar
• Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23:965 - 72; http://dx.doi.org/10.1200/JCO.2005.06.124; PMID: 15613696
   PubMed Web of Science ®Google Scholar
• Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, et al. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat 2007; 10:13 - 29; http://dx.doi.org/10.1016/j.drup.2007.01.003; PMID: 17303468
   PubMed Web of Science ®Google Scholar
• Lamers F, van der Ploeg I, Schild L, Ebus ME, Koster J, Hansen BR, et al. Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe. Endocr Relat Cancer 2011; 18:657 - 68; http://dx.doi.org/10.1530/ERC-11-0207; PMID: 21859926
   PubMed Web of Science ®Google Scholar
• Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell 1999; 98:295 - 303; http://dx.doi.org/10.1016/S0092-8674(00)81959-5; PMID: 10458605
   PubMed Web of Science ®Google Scholar
• Ishola TA, Chung DH. Neuroblastoma. Surg Oncol 2007; 16:149 - 56; http://dx.doi.org/10.1016/j.suronc.2007.09.005; PMID: 17976976
   PubMed Web of Science ®Google Scholar
• Clevenger CV. Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol 2004; 165:1449 - 60; http://dx.doi.org/10.1016/S0002-9440(10)63403-7; PMID: 15509516
   PubMed Web of Science ®Google Scholar
• Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26:3291 - 310; http://dx.doi.org/10.1038/sj.onc.1210422; PMID: 17496923
   PubMed Web of Science ®Google Scholar